Updating the database of the Illinois Compiled Statutes (ILCS) is an ongoing process.
Recent laws may not yet be included in the ILCS database, but they are found on this site as Public
soon after they become law. For information concerning the relationship between statutes and Public Acts, refer to the
Because the statute database is maintained primarily for legislative drafting purposes,
statutory changes are sometimes included in the statute database before they take effect.
If the source note at the end of a Section of the statutes includes a Public Act that has
not yet taken effect, the version of the law that is currently in effect may have already
been removed from the database and you should refer to that Public Act to see the changes
made to the current law.
(305 ILCS 5/5-30.11)
(Text of Section from P.A. 101-10)
Treatment of autism spectrum disorder.
Treatment of autism spectrum disorder through applied behavior analysis shall be covered under the medical assistance program under this Article for children with a diagnosis of autism spectrum disorder when ordered by a physician licensed to practice medicine in all its branches and rendered by a licensed or certified health care professional with expertise in applied behavior analysis. Such coverage may be limited to age ranges based on evidence-based best practices. Appropriate State plan amendments as well as rules regarding provision of services and providers will be submitted by September 1, 2019.
(Source: P.A. 101-10, eff. 6-5-19.)
(Text of Section from P.A. 101-62)
Medicaid managed care organizations; preferred drug lists.
(a) No later than January 1, 2020, the Illinois Department shall develop a standardized format for all Medicaid managed care organization preferred drug lists in collaboration with Medicaid managed care organizations and other stakeholders, including, but not limited to, organizations that serve individuals impacted by HIV/AIDS or epilepsy, and community-based organizations, providers, and entities with expertise in drug formulary development.
(b) Following development of the standardized Preferred Drug List format, the Illinois Department shall allow Medicaid managed care organizations 6 months from the date of completion to comply with the new Preferred Drug List format. Each Medicaid managed care organization must post its preferred drug list on its website without restricting access and must update the preferred drug list posted on its website. Medicaid managed care organizations shall publish updates to their preferred drug lists no less than 30 days prior to the date upon which any update or change takes effect, including, but not limited to, any and all changes to requirements for prior approval requirements, step therapy, or other utilization controls.
(c)(1) No later than January 1, 2020, the Illinois Department shall establish and maintain the Illinois Drug and Therapeutics Advisory Board. The Board shall have the authority and responsibility to provide recommendations to the Illinois Department regarding which drug products to list on the Illinois Department's preferred drug list. The Illinois Department shall provide administrative support to the Board and the Board shall:
(A) convene and meet no less than once per calendar
(B) provide regular opportunities for public comment;
(C) comply with the provisions of the Open Meetings
All correspondence related to the Board, including correspondence to and from Board members, shall be subject to the Freedom of Information Act.
(2) The Board shall consist of the following voting members, all of whom shall be appointed by the Governor and shall serve terms of 3 years without compensation:
(A) one pharmacist licensed to practice pharmacy in
Illinois who is recommended by a statewide organization representing pharmacists;
(B) 4 physicians, recommended by a statewide
organization representing physicians, who are licensed to practice medicine in all its branches in Illinois, have knowledge of and adhere to best practice standards, and have experience treating Illinois Medicaid beneficiaries;
(C) at least one clinician who specializes in the
prevention and treatment of HIV, recommended by an HIV healthcare advocacy organization;
(D) at least one clinician recommended by a
healthcare advocacy organization that serves individuals who are affected by chronic diseases that require significant pharmaceutical treatments;
(E) one clinician representing the Illinois
(F) one licensed psychiatrist, recommended by a
statewide organization representing psychiatrists, who has experience treating Illinois Medicaid beneficiaries.
One non-voting clinician recommended by an association of Medicaid managed care health plans shall serve a term of 3 years on the Board without compensation.
Organizations interested in nominating non-voting clinicians to advise the Board may submit requests to participate to the Illinois Department.
A licensed physician recommended by the Rare Disease Commission who is a rare disease specialist and possesses scientific knowledge and medical training with respect to rare diseases and is familiar with drug and biological products and treatment shall be notified in advance to attend an Illinois Drug and Therapeutics Advisory Board meeting when a drug or biological product is scheduled to be reviewed in order to advise and make recommendations on drugs or biological products.
(d) The Illinois Department shall adopt rules, to be in place no later than January 1, 2020, for the purpose of establishing and maintaining the Board.
(Source: P.A. 101-62, eff. 7-12-19.)
(Text of Section from P.A. 101-209)
Managed care reports; minority-owned and women-owned businesses.
Each Medicaid managed care health plan shall submit a report to the Department by March 1, 2020, and every March 1 thereafter, that includes the following information:
(1) The administrative expenses paid to the Medicaid
managed care health plan.
(2) The amount of money the Medicaid managed care
health plan has spent with Business Enterprise Program certified businesses.
(3) The amount of money the Medicaid managed care
health plan has spent with minority-owned and women-owned businesses that are certified by other agencies or private organizations.
(4) The amount of money the Medicaid managed care
health plan has spent with not-for-profit community-based organizations serving predominantly minority communities, as defined by the Department.
(5) The proportion of minorities, people with
disabilities, and women that make up the staff of the Medicaid managed care health plan.
(6) Recommendations for increasing expenditures with
minority-owned and women-owned businesses.
(7) A list of the types of services to which the
Medicaid managed care health plan is contemplating adding new vendors.
(8) The certifications the Medicaid managed care
health plan accepts for minority-owned and women-owned businesses.
(9) The point of contact for potential vendors
seeking to do business with the Medicaid managed care health plan.
The Department shall publish the reports on its website and shall maintain each report on its website for 5 years. In May of 2020 and every May thereafter, the Department shall hold 2 annual public workshops, one in Chicago and one in Springfield. The workshops shall include each Medicaid managed care health plan and shall be open to vendor communities to discuss the submitted plans and to seek to connect vendors with the Medicaid managed care health plans.
(Source: P.A. 101-209, eff. 8-5-19.)